Exploring the Potential of Melanotan 2 Peptide & Buy Research Peptides
Drlogy

Drlogy

Healthcare organization


Exploring the Potential of Melanotan 2 Peptide & Buy Research Peptides

Are you interested in learning more about the research peptide Melanotan 2? Researchers will find all the necessary information on this peptide in the article below, including research findings on the peptide in areas of sexual function and tanning/pigmentation.

Studies suggest Melanotan-II, often known as MT-II or Melanotan 2, is a manufactured peptide that may allow for artificial tanning by imitating the actions of the α-melanocyte stimulating hormone.

Research indicates that Melanotan 2 may potentially mitigate symptoms of erectile dysfunction, as suggested by studies in male animal models, and may also potentially increase sexual desire, in addition to pigmenting the skin. Investigations purport that MT-II may potentially bind to melanocortin receptors across the organism, affecting metabolism, hunger, and cognition.

 

Melanotan 2 Peptide: What Is It?

Findings imply that a synthetic peptide called Melanotan 2 (MT-II) may bind non-selectively to melanocortin receptors throughout the organism. It has been hypothesized to affect metabolism, sexual desire, and skin pigmentation.

 

Researchers at the University of Arizona first synthesized and analyzed the MT-II peptide to create a synthetic peptide with enhanced melanogenic activity compared to the natural peptide hormone alpha-melanocyte stimulating hormone (α-MSH).

 

To create a hypothetically effective synthetic peptide Melanotan 2, they subjected the naturally occurring 13-amino acid peptide, α-MSH, to a sequence of chemical and amino acid changes. With its enhanced affinity and resistance to enzymatic degradation, Melanotan 2 is theorized to bind to the melanocortin receptor for longer durations, allowing for supraphysiological levels of melanogenesis.

 

Like α-MSH, Melanotan 2 appears to bind to at least four of five melanocortin receptor subtypes (MC1R MC5R). Thus, Melanotan 2 is believed to be an agonist for melanocortin receptors 1, 3, 4, and 5; however, it is not selective.

 

Melanotan 2 Peptide: Tanning, Pigmentation

Researchers studying the potential impacts of MT-II in animal research models have suggested the peptide may induce pigmentation or tanning in the skin, without the need for UV exposure by sunshine. Scientists also speculate that exposure to the peptide may be a possible way to protect skin cells from sun damage. Statistically significant skin darkening was speculated in all research models given MT-II in the original phase I clinical study for the peptide, which aimed to assess its properties and tanning potential.

 

Studies in MT-II on pigmentation speculated the peptide may also induce erections in the male species they were evaluating. Scientists looked into how it may have affected sexual function and suggested that it might exhibit potential in both organic and psychogenic erectile dysfunction.

 

Scientists made a chemical adjustment to the peptide, switching out one -NH2 group for a -OH group to render the molecule active during sexual processes.

 

Melanotan 2 Peptide Potential

Since the first experiment of Melanotan 2 in 1996, researchers have speculated several unanticipated properties of the peptide. These properties are believed to be connected to the recently discovered biology of the melanocortin system.

 

Numerous studies have suggested that Melanotan 2 may have potential impacts on

  • Hunger
  • Insulin sensitivity
  • Cognition, and
  • Speculated potential for tanning and sexual arousal.

 

Melanotan 2 and Erectile Dysfunction (ED)

While first studied for its tanning and skin protection properties, Melanotan 2's properties for erectile dysfunction and sexual activity were found to be surprising. After the initial phase I study of MT-II, researchers shifted their emphasis to the potential properties of MT-II for sexual activity since the research models they were evaluating in previous studies were observed to induce greater erections after being exposed to the compound.

 

This redirected attention allowed for a subsequent evaluation of Melanotan 2's potential in the context of psychogenic erectile dysfunction (ED) in male mammal models.

Within the six-hour observation period after presentation, 80% of research models of erectile dysfunction appeared to experiencing erections, according to the study's authors. Even in male models whose erectile dysfunction was deemed organic (i.e., caused by physical factors), many follow-up studies have suggested that MT-II may improve erections.

 

Subsequent research indicated that MT-II might modify sexual arousal by interacting with two receptors in the central nervous system, MC-3, and MC-4, distinct from the tanning-inducing MC-1 receptors in melanocytes.

 

Melanotan 2 Peptide and Arousal

Since it has been speculated that the MC4R may play a role in regulating female sexual function, Melanotan 2 studies have sought to examine female research models of sexual arousal issues, to determine if the dysfunction might be addressed by the peptide acting on the same receptor.

 

MT-II might act on melanocortin receptors mainly in the brain rather than in the peripheral, a hypothesis which is connected to the fact that it seems effective in both sexes, which is surprising given the difference in sexual architecture between the sexes.

 

In considering MT-II and female sexual desire, the vast literature on PT-141 is pertinent since Bremelanotide (PT-141) is a naturally occurring metabolite of MT-II. Initial trials of the MT-II metabolite Bremelanotide suggested that the compound may increase libido.

 

Please note that none of the substances mentioned in this article have been approved for human or animal consumption and should, therefore, not be acquired or utilized by unlicensed individuals outside of contained research settings such as laboratories. Professionals may Buy Research Peptides on the Biotech Peptides website.

 

References

  • Hadley, M. E., & Dorr, R. T. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides, 27(4), 921– 930. https://doi.org/10.1016/j.peptides.2005.01.029
  • Costantino, H. R., Illum, L., Brandt, G., Johnson, P. H., & Quay, S. C. (2007). Intranasal delivery: physicochemical and therapeutic aspects. International journal of pharmaceutics, 337(1-2), 1– 24. https://doi.org/10.1016/j.ijpharm.2007.03.025
  • Hadley, M. E., Marwan, M. M., al-Obeidi, F., Hruby, V. J., &Castrucci, A. M. (1989). Linear and cyclic alpha[1]melanotropin [4-10]-fragment analogues that exhibit superpotency and residual activity. Pigment cell research, 2(6), 478–484. https://doi.org/10.1111/j.1600-0749.1989.tb00242.x
  • Dorr, R. T., Lines, R., Levine, N., Brooks, C., Xiang, L., Hruby, V. J., & Hadley, M. E. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life sciences, 58(20), 1777–1784. https://doi.org/10.1016/0024-3205(96)00160-9
  • Hadley, M. E., Hruby, V. J., Blanchard, J., Dorr, R. T., Levine, N., Dawson, B. V., al-Obeidi, F., & Sawyer, T. K. (1998). Discovery and development of novel melanogenic drugs. Melanotan-I and -II. Pharmaceutical biotechnology, 11, 575–595. https://doi.org/10.1007/0-306-47384-4_25

 

favorite_border 879 Likes

DOCTOR’S MOST TRUSTED HEALTHCARE PLATFORM

10M+

Patients

22000+

Doctors

20000+

Hospitals/Labs

Drlogy®
The Power To Health

Copyright © 2024 Drlogy. All rights reserved.